Flagship record · Semaglutide

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

human primaryhigh controlled human primaryprimary subject

Scientific attribution

The source directly studies the governed peptide as an intervention, including comparison between doses or regimens of the same peptide.

PMID: 33667417
DOI: 10.1016/S0140-6736(21)00213-0
Sample size: 1210
Population / model: 1210 adults with overweight or obesity and type 2 diabetes

Intervention / comparator

Semaglutide 2.4 mg once weekly vs Semaglutide 1.0 mg and placebo

Outcomes

Percent body-weight change at 68 weeks
At least 5% weight reduction
Adverse events

Key findings

Mean body-weight change was -9.6% with semaglutide 2.4 mg versus -3.4% with placebo.
68.8% of evaluated participants receiving semaglutide 2.4 mg achieved at least 5% weight reduction versus 28.5% with placebo.
Gastrointestinal adverse events were more frequent with semaglutide than placebo.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.